| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RPL35A |
| Uniprot No | P18077 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-110aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSGRLWS KAIFAGYKRG LRNQREHTAL LKIEGVYARD ETEFYLGKRC AYVYKAKNNT VTPGGKPNKT RVIWGKVTRA HGNSGMVRAK FRSNLPAKAI GHRIRVMLYP SRI |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RPL35A重组蛋白的模拟参考文献示例(仅供参考，实际文献需通过学术数据库查询)：
---
1. **标题**：*Recombinant RPL35A Protein Expression and Purification in Escherichia coli*
**作者**：Zhang Y, et al.
**摘要**：研究报道了利用大肠杆菌表达系统成功表达并纯化带有His标签的RPL35A重组蛋白，通过SDS-PAGE和Western blot验证其分子量及纯度，并证实其在体外核糖体组装中的功能活性。
2. **标题**：*RPL35A Overexpression Promotes Tumor Proliferation in Colorectal Cancer*
**作者**：Lee S, et al.
**摘要**：研究发现RPL35A在结直肠癌组织中高表达，通过重组RPL35A蛋白处理细胞系，证明其通过激活mTOR信号通路促进肿瘤细胞增殖，提示其作为潜在治疗靶点。
3. **标题**：*Structural Insights into RPL35A’s Role in Ribosome Biogenesis*
**作者**：Smith J, et al.
**摘要**：利用重组RPL35A蛋白进行冷冻电镜分析，揭示了其在核糖体大亚基组装中的关键结构域，并发现其缺失会导致核糖体RNA加工异常，影响蛋白质合成效率。
4. **标题**：*RPL35A Mutation Analysis and Functional Rescue by Recombinant Protein*
**作者**：Garcia R, et al.
**摘要**：在遗传性骨髓衰竭综合征患者中发现RPL35A基因突变，通过体外表达野生型重组RPL35A蛋白恢复了突变细胞的核糖体功能，为基因治疗提供依据。
---
**备注**：以上为模拟示例，实际文献请通过PubMed、Google Scholar或Web of Science等平台，以关键词“RPL35A recombinant protein”或“RPL35A function”检索。真实研究可能涉及疾病机制、结构生物学或分子调控等领域。
RPL35A (Ribosomal Protein L35a) is a component of the 60S large ribosomal subunit, playing a critical role in protein synthesis and ribosome assembly. As part of the ribosome, it facilitates mRNA decoding and peptide bond formation. The gene encoding RPL35A is evolutionarily conserved across eukaryotes, underscoring its functional importance. Dysregulation of RPL35A has been implicated in various pathologies, including cancer and Diamond-Blackfan anemia (DBA), a rare bone marrow failure disorder linked to ribosomal protein mutations.
Recombinant RPL35A protein is engineered using heterologous expression systems, such as *E. coli* or mammalian cell cultures, to produce purified, functional protein for research. This involves cloning the RPL35A coding sequence into expression vectors, followed by induction, lysis, and affinity chromatography-based purification. Recombinant versions often include tags (e.g., His-tag) for ease of isolation. Studies leveraging recombinant RPL35A aim to elucidate its structural interactions within the ribosome, post-translational modifications, and extra-ribosomal roles in cell cycle regulation or apoptosis.
In cancer biology, RPL35A overexpression has been observed in hepatocellular carcinoma and colorectal cancer, correlating with poor prognosis. Its recombinant form enables in vitro and in vivo studies to explore mechanisms driving tumorigenesis or chemoresistance. Additionally, RPL35A mutations in DBA disrupt erythropoiesis, and recombinant protein models help dissect these pathways. As a therapeutic target, recombinant RPL35A aids in screening small molecules or gene therapies aimed at restoring ribosomal function. Overall, RPL35A recombinant protein serves as a vital tool for advancing molecular and translational research in ribosomopathies and cancer. (Word count: 246)
×
